Back to Journals » The Application of Clinical Genetics » Volume 2

Association of the BANK1 R61H variant with systemic lupus erythematosus in Americans of European and African ancestry



Struan FA Grant1,2,3, Michelle Petri4, Jonathan P Bradfield1, Cecilia E Kim1, Erin Santa1, Kiran Annaiah1, Edward C Frackelton1, Joseph T Glessner1, F George Otieno1, Julie L Shaner1, Ryan M Smith1, Andrew W Eckert1, Rosetta M Chiavacci1, Marcin Imielinski1, Kathleen E Sullivan5, Hakon Hakonarson1,2,3

1Center for Applied Genomics, Abramson Research Center, The Children’s Hospital of Philadelphia, Philadelphia, PA, USA; 2Department of Pediatrics and Division of Human Genetics, The Children’s Hospital of Philadelphia, Philadelphia, PA, USA; 3Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA; 4Division of Rheumatology, Johns Hopkins School of Medicine, Baltimore, MD, USA; 5Division of Allergy and Immunology, Abramson Research Center, The Children’s Hospital of Philadelphia, Philadelphia, PA, USA

Abstract: Recently an association was demonstrated between the single nucleotide polymorphism (SNP), rs10516487, within the B-cell gene BANK1 and systemic lupus erythematosus (SLE) as a consequence of a genome wide association study of this disease in European and Argentinean populations. In a bid for replication, we examined the effects of the R61H non-synonymous variant with respect to SLE in our genotyped American cohorts of European and African ancestry. Utilizing data from our ongoing genome-wide association study in our cohort of 178 Caucasian SLE cases and 1808 Caucasian population-based controls plus 148 African American (AA) SLE cases and 1894 AA population-based controls we investigated the association of the previously described non-synonymous SNP at the BANK1 locus with the disease in the two ethnicities separately. Using a Fisher’s exact test, the minor allele frequency (MAF) of rs10516487 in the Caucasian cases was 22.6% while it was 31.2% in Caucasian controls, yielding a protective odds ratio (OR) of 0.64 (95% CI 0.49–0.85; one-sided p = 7.07 × 10−4). Furthermore, the MAF of rs10516487 in the AA cases was 18.7% while it was 23.3% in AA controls, yielding a protective OR of 0.75 (95% CI 0.55–1.034; one-sided p = 0.039). The OR of the BANK1 variant in our study cohorts is highly comparable with that reported previously in a South American/European SLE case-control cohort (OR = 0.72). As such, R61H in the BANK1 gene confers a similar magnitude of SLE protection, not only in European Americans, but also in African Americans.

Keywords: systemic lupus erythematosus, African Americans, European Americans, BANK1 gene

Creative Commons License © 2008 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.